The Second Quarter Academic Exchange Conference of the Andrology Branch of Taizhou Medical Association in 2025 has been successfully concluded. This conference focused on cutting-edge diagnostic and treatment technologies in andrology, offering a feast of academic knowledge to professionals in the field.

At the conference, Professor Li Feiping from Taizhou Enze Hospital gave an impressive presentation titled "Application and Prospects of Low-Intensity Pulsed Ultrasound (LIPUS) in Andrology Diseases." He showcased two representative cases from his department, clearly demonstrating the significant therapeutic effect of WBL LIPUS through image comparisons before and after treatment using the RigiScan Plus penile hardness meter. Additionally, Professor Li shared valuable experiences from Shanghai First People's Hospital and Nanjing Gulou Hospital, as well as findings from multi-center clinical research.

It is noteworthy that a multi-center, randomized, double-blind, placebo-controlled clinical study on the treatment of mild to moderate erectile dysfunction (ED) with WBL LIPUS, conducted in collaboration with Peking University First Hospital and several other hospitals, confirmed its safety and efficacy in treating erectile dysfunction.

Moreover, Professor Li Feiping expressed high expectations for the application of LIPUS in treating penile fibrosclerosis, stress urinary incontinence, chronic prostatitis, and male functional rehabilitation and maintenance. This exchange conference provided new perspectives on the treatment of male diseases and contributed to advancing the industry to new heights.

Innovative Research on WBL LIPUS

The innovative development of WBL LIPUS technology was driven and guided by Academician Guo Yinglu from the Chinese Academy of Engineering, in collaboration with Professor Lv Futai and Professor Lin Guiting from the University of California, San Francisco (UCSF), and Professor Xin Zhongcheng from Peking University First Hospital. After years of multinational collaborative research, they established the optimal parameter combination for LIPUS treatment, including frequency, pulse intensity, and emission mode, and developed a comprehensive theoretical mechanism and technological platform. At the same time, Professors Xia Shujie and Li Zheng from Shanghai Jiaotong University School of Medicine led the initiation of China’s first multi-center, randomized controlled clinical study on LIPUS, systematically validating the effectiveness and safety of LIPUS in functional rehabilitation under different treatment frequencies, providing strong support for the standardized promotion of this technology and the formulation of clinical guidelines.

Technical Principles of WBL LIPUS for Treating Erectile Dysfunction (ED)

The core mechanism of WBL LIPUS is the use of low-energy pulsed ultrasound (acoustic intensity range of 50-350mW/CM²) to target the penile corpora cavernosa tissue, activating endogenous stem cells, promoting the regeneration of blood vessels and nerves, and repairing damaged vascular endothelium and nerve matrix. This leads to improvements in erectile function at the pathological level. Unlike traditional oral medications (such as PDE5 inhibitors), prosthesis implantation, or invasive therapies (such as intracavernous injections), LIPUS does not rely on drugs or surgery, avoiding side effects and the inconvenience of repeated treatments.

WBL LIPUS

WBL Medical Equipment Co., Ltd. is the pioneer of LIPUS technology. With its self-developed WBL-ED device, it was the first to apply low-intensity pulsed ultrasound technology to the treatment of erectile dysfunction, providing a non-invasive, safe, and efficient new solution. Since receiving approval from the China Food and Drug Administration (CFDA) in 2018, WBL LIPUS has not only filled the technological gap in this field both domestically and internationally but has also won the China National Medical Device Innovation Product award, highlighting WBL's leading position and technological strength in the industry.